Astellas Pharma Gmbh

The University of Tokyo

Seiji Takae

Atsushi Sakurai

Kazunori Kataoka

Hiroyuki Kojima

Tetsuya Tamura

Masakazu Miyazaki

Toshiro Sakai

Ko Tanaka

Yuichi Yamasaki

Hiroaki Tasaki

Yuki Kasashima

Akihiko Sasaki

Yurina Ansei

Tsuyoshi Kiyota

Atsushi Muro

Provided is a pharmaceutical composition containing 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof and a sweetener for reducing the bitterness of gilteritinib, suppressing the decrease in dissolution stability of gilteritinib due to, for example, stress such as heat and/or humidity over time, and having excellent dissolution stability. The pharmaceutical composition contains gilteritinib or a pharmaceutically acceptable salt thereof, a sweetener, and sugars and/or sugar alcohols.

Pharmaceutical composition

To provide: (1) a modified release liquid (suspension) containing mirabegron, (2) a ready-to-suspend pharmaceutical composition containing mirabegron, and (3) a mirabegron-containing pharmaceutical composition that does not generate undissolved lumps, even when it is suspended at the time of use. The present invention relates to a pharmaceutical composition containing a complex of mirabegron or a pharmaceutically acceptable salt thereof with sodium polystyrene sulfonate.

Pharmaceutical composition containing mirabegron

A pharmaceutical composition containing, as the active ingredient, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, of which the solubility in an acidic pH region is different from that in a neutral pH region, with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance, is provided. The pharmaceutical composition for oral administration of the present invention contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and a hydrophilic lubricant, and is useful as a pharmaceutical composition for oral administration with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance.

Pharmaceutical composition for oral administration

It is an object of the present invention to provide a polyion complex used as a non-viral gene vector, which achieves sufficiently high gene expression efficiency to a target cell. The polyion complex of the present invention comprises a block copolymer formed by binding polyethylene glycol to polycation via a disulfide group and a nucleic acid.

Polymer micelle complex including nucleic acid

Growing community of inventors

Tokyo, Japan

Seiji Takae